ACRS

Aclaris Therapeutics, Inc. NASDAQ

Healthcare ·Medical - Diagnostics & Research ·US · aclaristx.com

$4.53

Mkt Cap $546.3M

52w Low $1.16 90.3% of range 52w High $4.89

50d MA $3.74 200d MA $2.77

P/E (TTM) -8.3x

EV/EBITDA -5.5x

P/B 5.2x

Debt/Equity 0.0x

ROE -63.0%

P/FCF -7.8x

RSI (14) —

ATR (14) —

Beta 0.68

50d MA $3.74

200d MA $2.77

Avg Volume 1.8M

About

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Con…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	-0.15	-0.16	-6.7%	3.13	-1.6%	-8.3%	-2.6%	-2.9%	-1.0%	-0.3%	—
Nov 6, 2025	AMC	-0.13	-0.12	+7.7%	2.27	-0.4%	+2.2%	-6.2%	+1.3%	+6.2%	+2.2%	—
Aug 7, 2025	AMC	-0.13	-0.13	+0.0%	1.57	+0.0%	+3.8%	+4.5%	+4.5%	+8.3%	+7.6%	—
May 8, 2025	AMC	-0.17	-0.12	+29.4%	1.31	-3.8%	-3.8%	-4.6%	-6.9%	-9.9%	-6.9%	—
Feb 27, 2025	AMC	-0.09	-0.10	-11.1%	1.95	-2.6%	+2.1%	+0.5%	-1.0%	-5.1%	-6.7%	—
Nov 6, 2024	AMC	-0.08	-0.11	-37.5%	2.26	+0.4%	+8.4%	+16.8%	+16.4%	+13.3%	+8.0%	—
Aug 7, 2024	AMC	-0.19	-0.15	+21.1%	1.19	+0.8%	-1.7%	-2.5%	-4.2%	+0.0%	-1.7%	—
May 7, 2024	AMC	-0.28	-0.24	+14.3%	1.34	-6.7%	-9.0%	-8.2%	-12.7%	-11.9%	-11.9%	—
Feb 27, 2024	AMC	-0.37	-0.30	+18.9%	1.20	+0.0%	-0.8%	-0.8%	+3.3%	+4.2%	+5.8%	—
Nov 6, 2023	AMC	-0.48	-0.41	+14.6%	5.48	+0.0%	-1.1%	-0.5%	-10.2%	-13.2%	-88.2%	—
Aug 7, 2023	AMC	-0.45	-0.42	+6.7%	9.14	-0.3%	-5.3%	-7.2%	-8.8%	-10.1%	-12.9%	—
May 8, 2023	AMC	-0.44	-0.42	+4.5%	8.40	-0.4%	-1.4%	-1.3%	-4.5%	-6.1%	-1.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 5	Guggenheim	Initiates	Buy	$12	—	—	—	—	—	—	—	—
Mar 31	Wedbush	Maintains	Outperform → Outperform	—	$3.49	$3.52	+0.9%	+7.4%	+18.6%	+20.3%	+8.9%	+7.4%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.66	$3.61	-1.4%	+2.2%	+0.8%	-2.2%	-9.8%	-1.9%
Jan 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.87	$3.90	+0.8%	-9.3%	-11.4%	-9.3%	-6.7%	-10.3%
Jan 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.43	$4.24	-4.3%	-0.2%	+2.3%	+1.6%	-13.8%	-12.6%
Oct 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.90	$1.97	+3.7%	+5.8%	+25.3%	+18.9%	+18.9%	+13.2%
Jun 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.52	$1.56	+2.6%	+7.2%	+2.6%	-3.3%	-6.6%	-7.2%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.22	$1.22	+0.0%	-3.3%	+0.0%	+7.4%	+6.6%	+10.7%
May 9	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$1.31	$1.26	-3.8%	-3.8%	-4.6%	-6.9%	-9.9%	-6.9%
Mar 18	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.58	$1.59	+0.6%	+0.0%	-1.9%	-0.6%	+1.3%	+7.6%
Dec 23	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$2.72	$2.99	+9.9%	+6.2%	+6.6%	+7.4%	+0.4%	-8.8%
Nov 19	Jefferies	Upgrade	Hold → Buy	—	$3.14	$3.71	+18.2%	+46.2%	+26.1%	+37.6%	+21.0%	+27.1%
Nov 19	Leerink Partners	Upgrade	Market Perform → Outperform	—	$3.14	$3.71	+18.2%	+46.2%	+26.1%	+37.6%	+21.0%	+27.1%
Nov 19	BTIG	Upgrade	Neutral → Buy	—	$3.14	$3.71	+18.2%	+46.2%	+26.1%	+37.6%	+21.0%	+27.1%
Nov 18	Piper Sandler	Upgrade	Neutral → Overweight	—	$2.05	$2.43	+18.5%	+53.2%	+123.9%	+93.2%	+110.7%	+85.4%
Jan 22	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$1.14	$1.19	+4.4%	+10.5%	+12.3%	+10.5%	+9.6%	+7.9%
Jan 11	BTIG	Downgrade	Buy → Neutral	—	$1.00	$0.97	-3.0%	-4.3%	-7.6%	+16.0%	+18.0%	+18.0%
Dec 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.07	$1.09	+1.9%	-1.9%	-1.9%	+4.7%	+2.8%	-0.9%
Dec 18	Stifel	Maintains	Hold → Hold	—	$1.01	$1.02	+1.0%	-7.2%	+1.0%	-7.4%	+0.0%	+5.9%
Nov 14	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$0.64	$0.67	+4.3%	+5.5%	+24.3%	+37.3%	+48.0%	+45.8%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.64	$0.67	+4.3%	+5.5%	+24.3%	+37.3%	+48.0%	+45.8%
Nov 13	William Blair	Downgrade	Outperform → Market Perform	—	$4.75	$0.70	-85.3%	-86.4%	-85.7%	-83.1%	-81.4%	-79.9%
Nov 13	Stifel	Downgrade	Buy → Hold	—	$4.75	$0.70	-85.3%	-86.4%	-85.7%	-83.1%	-81.4%	-79.9%
Oct 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$6.06	$6.05	-0.2%	-5.0%	-0.5%	-2.6%	-8.6%	-12.2%
Oct 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.26	$6.20	-1.0%	-3.8%	-5.4%	-3.2%	-8.0%	-3.7%
Sep 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.43	$7.42	-0.1%	-0.4%	-8.9%	-8.2%	-10.5%	-11.7%
Sep 19	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$7.43	$7.42	-0.1%	-0.4%	-8.9%	-8.2%	-10.5%	-11.7%
Sep 14	Stifel	Maintains	Buy → Buy	—	$7.58	$7.94	+4.7%	+5.5%	-0.4%	-2.0%	-2.4%	-10.7%
Aug 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.14	$9.11	-0.3%	-5.3%	-7.2%	-8.8%	-10.1%	-12.9%
Jun 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.46	$9.50	+0.4%	+0.7%	+4.8%	+8.0%	+12.3%	+12.5%
Mar 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.07	$7.07	+0.0%	+4.8%	+11.5%	+8.3%	+11.6%	+16.8%
Mar 7	BTIG	Maintains	Buy → Buy	—	$7.07	$7.07	+0.0%	+4.8%	+11.5%	+8.3%	+11.6%	+16.8%
Mar 7	Goldman Sachs	Maintains	Buy → Buy	—	$7.07	$7.07	+0.0%	+4.8%	+11.5%	+8.3%	+11.6%	+16.8%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.77	$12.53	-1.9%	-5.5%	-5.1%	-2.4%	-4.2%	-1.2%
Feb 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$13.73	$13.91	+1.3%	+2.5%	-0.1%	+0.9%	+4.1%	-1.5%
Dec 14	Stifel	Maintains	Buy → Buy	—	$15.94	$16.33	+2.4%	+1.4%	-1.8%	-2.2%	-8.4%	-5.6%
Dec 1	Goldman Sachs	Maintains	Buy → Buy	—	$15.22	$15.46	+1.6%	+4.2%	+9.3%	+2.8%	+4.6%	-0.3%
Oct 6	BTIG	Maintains	Buy → Buy	—	$15.75	$16.41	+4.2%	+6.0%	+0.4%	-1.7%	-3.7%	-2.1%
Jun 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.81	$18.32	+2.9%	+1.0%	+2.0%	+2.7%	+0.6%	+1.0%
Jun 15	Piper Sandler	Maintains	Overweight → Overweight	—	$17.83	$18.50	+3.8%	-0.1%	+0.9%	+1.9%	+2.6%	+0.4%
Apr 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.46	$27.15	+2.6%	+2.8%	+1.2%	+0.9%	-1.5%	-7.0%
Mar 4	SVB Leerink	Maintains	Outperform → Outperform	—	$21.98	$21.76	-1.0%	-3.8%	-3.0%	-3.4%	+2.2%	+3.8%
Jan 20	SVB Leerink	Maintains	Outperform → Outperform	—	$18.83	$19.95	+5.9%	-4.6%	-4.2%	-3.2%	-6.3%	-7.2%
Oct 23	SVB Leerink	Upgrade	Market Perform → Outperform	—	$1.61	$1.62	+0.6%	+2.5%	+4.3%	+10.6%	+3.1%	+18.0%
Oct 22	SVB Leerink	Upgrade	Market Perform → Outperform	—	$1.41	$1.56	+10.6%	+14.2%	+17.0%	+19.1%	+26.2%	+17.7%
Sep 6	JMP Securities	Downgrade	Market Outperform → Market Perform	—	$0.92	$0.88	-4.5%	+9.7%	+12.9%	+21.6%	+20.5%	+17.3%
Aug 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$0.99	$0.95	-4.0%	-9.1%	-14.2%	-16.4%	-20.6%	-19.2%
Jun 27	SVB Leerink	Downgrade	Outperform → Market Perform	—	$4.45	$2.88	-35.3%	-52.1%	-50.8%	-45.4%	-47.4%	-44.5%
May 6	SVB Leerink	Maintains	Outperform → Outperform	—	$6.34	$6.28	-0.9%	+4.1%	+5.4%	+3.6%	-6.5%	-5.5%
Oct 16	JMP Securities	Upgrade	Market Perform → Market Outperform	—	$13.41	$13.25	-1.2%	-7.1%	-9.2%	-9.2%	-6.8%	-6.6%

Recent Filings

8-K · 8.01 !! High

Aclaris Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement

Aclaris Therapeutics announced positive ATI-2138 trial results for its ATI-052 candidate, potentially advancing the company's clinical pipeline and supporting future regulatory submissions.

Apr 28

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

ACRS disclosed emerging growth company status via Regulation FD, potentially signaling lower compliance burdens and reduced disclosure requirements that may attract growth-focused investors but warrant scrutiny of financial reporting depth.

Mar 11

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

ACRS disclosed emerging growth company status via Regulation FD, potentially signaling access to reduced disclosure requirements and regulatory relief that could lower compliance costs and improve near-term profitability.

Mar 10

8-K

Aclaris Therapeutics, Inc. -- 8-K Filing

Aclaris Therapeutics reported 2025 fourth-quarter and full-year financial results while maintaining its focus on immuno-inflammatory disease treatments, with CEO Neal Walker providing strategic corporate updates to investors.

Feb 26

Data updated apr 24, 2026 10:42am · Source: massive.com